<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786707</url>
  </required_header>
  <id_info>
    <org_study_id>20070881</org_study_id>
    <nct_id>NCT01786707</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus</brief_title>
  <acronym>HOT</acronym>
  <official_title>Phase 2 Study of Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diabetes Research Institute Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open labeled, randomized controlled clinical trial comparing the benefit of&#xD;
      both hyperbaric oxygen therapy and intrapancreatic stem cell infusion to standard medical&#xD;
      treatment alone for type 2 diabetes mellitus. Subjects will receive standard medical&#xD;
      treatment (SMT) with insulin and metformin for 4 months (evaluation phase). Then they will be&#xD;
      randomized into either the intervention group or the control group:&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, prospective, randomized case controlled study in patients with Type 2&#xD;
      Diabetes Mellitus (T2DM) that seeks to investigate whether the combination of intrapancreatic&#xD;
      Autologous Stem Cell infusion (ASC) and Hyperbaric Oxygen treatment (HBO) can improve&#xD;
      glycemic control and pancreatic function in T2DM patients compared to controls receiving&#xD;
      standard medical treatment (SMT) with metformin and insulin alone.&#xD;
&#xD;
      New therapies that lead to stopping ß-cell damage and possible ß-cell regeneration may&#xD;
      decrease the incidence and progression of T2DM chronic complications and together with&#xD;
      achievable life style changes may improve general health and quality of life of T2DM&#xD;
      patients. Preliminary data from a pilot study involving 25 subjects with T2DM that underwent&#xD;
      a combined treatment using ASC+HBO showed a significant progressive and consistent reduction&#xD;
      in plasma glucose and HbA1c with an increase in C-peptide in conjunction with a decrease in&#xD;
      the number and dose of oral agents and/or insulin. These encouraging preliminary results&#xD;
      require confirmation in a controlled, randomized prospective trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Reduction of HbA1c of &gt;0.5%</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Subjects With a Reduction of &gt;1% in HbA1c</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous stem cells and hyperbaric oxygen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in a control group will continue with standard medical treatment (Insulin and Metformin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous stem cells</intervention_name>
    <description>Pancreatic artery infusion of Autologous Stem cells.</description>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperbaric oxygen therapy</intervention_name>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin dose as per clinical management</description>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin dose as tolerated</description>
    <arm_group_label>Autologous SC and HOT</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients age 45 to 65 years of age.&#xD;
&#xD;
          2. Ability to provide written informed consent.&#xD;
&#xD;
          3. Mentally stable and able to comply with the procedures of the study protocol.&#xD;
&#xD;
          4. Clinical history compatible with type 2 diabetes as defined by the Expert Committee on&#xD;
             the Diagnosis and classification of Diabetes Mellitus.&#xD;
&#xD;
          5. Onset of Type 2 DM disease at 40 years of age.&#xD;
&#xD;
          6. T2DM duration: 2-15 years at the time of enrollment.&#xD;
&#xD;
          7. Basal C-peptide: 0.3 ng/mL&#xD;
&#xD;
          8. HbA1c of 7.5-12.5% before standard medical therapy. Patients must have been treated&#xD;
             with SMT for minimum of 4 months prior to randomization. Insulin and metformin doses&#xD;
             should be stable over the 3 months prior to randomization.&#xD;
&#xD;
          9. HbA1c: 7.5-9.5% at time of randomization.&#xD;
&#xD;
         10. Total insulin daily dose at baseline and at randomization &lt;100 units/day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt;40 kg/m2.&#xD;
&#xD;
          2. Insulin requirements of &gt;100 U/day, and HbA1c &gt;9.5%&#xD;
&#xD;
          3. C-reactive protein &gt;10.00&#xD;
&#xD;
          4. Uncontrolled blood pressure: Systolic Blood Pressure &gt;140 mmHg or Diastolic Blood&#xD;
             Pressure &gt;80 mmHg Evidence of renal dysfunction, serum creatinine &gt; 1.5 mg/dl (males)&#xD;
             and 1.4 mg/dl (females)&#xD;
&#xD;
          5. Proteinuria &gt;300 mg/day&#xD;
&#xD;
          6. History or EKG evidence of myocardial infarction or any degree of heart failure&#xD;
&#xD;
          7. Female participants: Positive pregnancy test, presently breast-feeding, or&#xD;
             unwillingness to use effective contraceptive measures for the duration of the study.&#xD;
             Male participants: intent to procreate 3 months before or after the intervention or&#xD;
             unwillingness to use effective measures of contraception.&#xD;
&#xD;
          8. Active infection including hepatitis B, hepatitis C, HIV, or Tuberculosis. Positive&#xD;
             tests are acceptable only if associated with a history of previous vaccination in the&#xD;
             absence of any sign of active infection.&#xD;
&#xD;
          9. Known active alcohol or substance abuse including cigarette/cigar smoking&#xD;
&#xD;
         10. Baseline Hgb below the lower limits of normal at the local laboratory; lymphopenia&#xD;
             (&lt;1,000/L), neutropenia (&lt;1,500/L), or thrombocytopenia (platelets &lt;100,000/L).&#xD;
&#xD;
         11. A history of Factor V deficiency or other coagulopathy defined by International&#xD;
             normalized ratio (INR) &gt;1.5, Partial thromboplastin time (PTT) &gt;40, Prothrombin time&#xD;
             (PT) &gt;15.&#xD;
&#xD;
         12. Acute or chronic pancreatitis.&#xD;
&#xD;
         13. Symptomatic peptic ulcer disease.&#xD;
&#xD;
         14. Hyperlipidemia despite medical therapy&#xD;
&#xD;
         15. Receiving treatment for a medical condition requiring chronic use of systemic&#xD;
             corticosteroids in the past six months.&#xD;
&#xD;
         16. Symptomatic cholecystolithiasis.&#xD;
&#xD;
         17. Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
         18. Admission to hospital for any reason in the 14 days prior to enrollment.&#xD;
&#xD;
         19. History or presence of active proliferative diabetic retinopathy or macular edema.&#xD;
&#xD;
         20. Any malignancy.&#xD;
&#xD;
         21. Hepatic enzyme levels upper normal limits.&#xD;
&#xD;
         22. Total bilirubin upper normal limits unless secondary to known benign condition.&#xD;
&#xD;
         23. Abdominal aortic aneurysm.&#xD;
&#xD;
         24. History of cerebro-vascular accident.&#xD;
&#xD;
         25. Any patient with acute or subacute decompensation from diabetes.&#xD;
&#xD;
         26. Any acute or chronic infectious condition that in the criteria of the investigator&#xD;
             would be a risk for the patient.&#xD;
&#xD;
         27. Hypoproteinemia, cachexia or terminal states; history of anorexia/bulimia; respiratory&#xD;
             insufficiency; history of chronic sinusitis (sinusitis lasting more than 8 weeks in&#xD;
             the past year) or recurrent acute sinusitis (sinusitis lasting more than 4 weeks more&#xD;
             than four times in the past year.&#xD;
&#xD;
         28. Any contraindication to hyperbaric oxygen treatment.&#xD;
&#xD;
         29. Subjects treated with any medication that could interfere with the outcome of the&#xD;
             study.&#xD;
&#xD;
         30. Subjects positive for auto-antibodies&#xD;
&#xD;
         31. History of Cushing syndrome (endogenous or iatrogenic).&#xD;
&#xD;
         32. History of allergy to iodine or iodinated materials.&#xD;
&#xD;
         33. Abnormal thyroid function&#xD;
&#xD;
         34. Any medical condition that, in the opinion of the investigator, will interfere with&#xD;
             the safe completion of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute, University of Miami Miller School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <results_first_submitted>December 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Director, Clinical Islet Transplant Program, Diabetes Research Institute</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Hyperbaric oxygen therapy (HOT)</keyword>
  <keyword>Autologous Bone Marrow-Derived Buffy Coat</keyword>
  <keyword>Stem cells (SC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous Stem Cell and HOT</title>
          <description>Autologous stem cells (SC) and hyperbaric oxygen therapy&#xD;
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Autologous SC and HOT</title>
          <description>Autologous stem cells and hyperbaric oxygen therapy&#xD;
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Reduction of HbA1c of &gt;0.5%</title>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous SC and HOT</title>
            <description>Autologous stem cells and hyperbaric oxygen therapy&#xD;
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Reduction of HbA1c of &gt;0.5%</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Subjects With a Reduction of &gt;1% in HbA1c</title>
        <time_frame>at 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous SC and HOT</title>
            <description>Autologous stem cells and hyperbaric oxygen therapy&#xD;
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With a Reduction of &gt;1% in HbA1c</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Autologous SC and HOT</title>
          <description>Autologous stem cells and hyperbaric oxygen therapy&#xD;
Autologous stem cells and hyperbaric oxygen therapy: Subjects will receive standard medical treatment (SMT) with insulin and metformin for 4 months. Then they will be randomized to either control or intervention groups. HOT and SC group: combination of HOT therapy and intrapancreatic autologous SC infusion in addition to SMT.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients in a control group will continue with standard medical treatment (SMT)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rodolfo Alejandro</name_or_title>
      <organization>University of Miami School of Medicine</organization>
      <phone>3052435324</phone>
      <email>ralejand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

